GB840870A - Improvements in or relating to insulin preparations - Google Patents
Improvements in or relating to insulin preparationsInfo
- Publication number
- GB840870A GB840870A GB22705/58A GB2270558A GB840870A GB 840870 A GB840870 A GB 840870A GB 22705/58 A GB22705/58 A GB 22705/58A GB 2270558 A GB2270558 A GB 2270558A GB 840870 A GB840870 A GB 840870A
- Authority
- GB
- United Kingdom
- Prior art keywords
- insulin
- solution
- exceed
- zinc
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
- 102000004877 Insulin Human genes 0.000 title abstract 6
- 108090001061 Insulin Proteins 0.000 title abstract 6
- 229940125396 insulin Drugs 0.000 title abstract 6
- 238000002360 preparation method Methods 0.000 title abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000000243 solution Substances 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 2
- -1 for example Substances 0.000 abstract 2
- 229910052751 metal Inorganic materials 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 229910021645 metal ion Inorganic materials 0.000 abstract 2
- 210000000496 pancreas Anatomy 0.000 abstract 2
- 229910052725 zinc Inorganic materials 0.000 abstract 2
- 239000011701 zinc Substances 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 229910052793 cadmium Inorganic materials 0.000 abstract 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 abstract 1
- 229910017052 cobalt Inorganic materials 0.000 abstract 1
- 239000010941 cobalt Substances 0.000 abstract 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 150000002736 metal compounds Chemical class 0.000 abstract 1
- 150000002739 metals Chemical class 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052759 nickel Inorganic materials 0.000 abstract 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 239000001632 sodium acetate Substances 0.000 abstract 1
- 235000017281 sodium acetate Nutrition 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/625—Extraction from natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A quick-acting insulin preparation is prepared by dissolving insulin derived from pig pancreas in an aqueous injectable medium having or being given a pH value of between 7 and 8. A solution of a compound of one or more metals that are prerequisite to the crystallization of insulin, i.e. zinc, cobalt, nickel or cadmium may be added providing the total metal content of the solution does not exceed about 13 X A X 10-13 milli equivalents per litre, A being the number of international units of insulin per millilitic. Buffering agents, for example, phosphate, citrate, acetate, borate, maleate, diethyl barbiturate and glycerol buffers may also be present. If the buffer used is capable of forming complexes with the metal ions present, the amount of metal compound added may exceed the above stated amount providing the free metal ions in solution do not exceed the limit. An example given is the preparation of an 0.02M aqueous solution of sodium acetate containing per litre 1.74 gms. (40,000 international units) of crystalline insulin derived from pig pancreas and containing about 0.7% zinc, 2 ml. N hydrochloric acid, 1 gm. methyl-p-hydroxybenzoate, 1.4% by weight NaCl, the pH being adjusted to 7.3 to 7.5 with sodium hydroxide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK840870X | 1957-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB840870A true GB840870A (en) | 1960-07-13 |
Family
ID=8153224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB22705/58A Expired GB840870A (en) | 1957-08-03 | 1958-07-15 | Improvements in or relating to insulin preparations |
Country Status (3)
| Country | Link |
|---|---|
| CY (1) | CY217A (en) |
| GB (1) | GB840870A (en) |
| MY (1) | MY6100048A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014118355A1 (en) | 2013-02-04 | 2014-08-07 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| WO2015104311A1 (en) * | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
| US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
| US9987332B2 (en) | 2011-09-01 | 2018-06-05 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
| US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
| US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
-
1958
- 1958-07-15 GB GB22705/58A patent/GB840870A/en not_active Expired
-
1961
- 1961-03-27 CY CY21761A patent/CY217A/en unknown
- 1961-12-31 MY MY6100048A patent/MY6100048A/en unknown
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10117909B2 (en) | 2008-10-17 | 2018-11-06 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1 agonist |
| US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist |
| US12303598B2 (en) | 2009-11-13 | 2025-05-20 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
| US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
| US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
| US10028910B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
| US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| US9987332B2 (en) | 2011-09-01 | 2018-06-05 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP3747426A1 (en) | 2013-02-04 | 2020-12-09 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| WO2014118355A1 (en) | 2013-02-04 | 2014-08-07 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9839675B2 (en) | 2013-02-04 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| CN105899191A (en) * | 2014-01-09 | 2016-08-24 | 赛诺菲 | Stabilized glycerol-free pharmaceutical preparations of insulin analogues and/or insulin derivatives |
| US10610595B2 (en) | 2014-01-09 | 2020-04-07 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CN105899191B (en) * | 2014-01-09 | 2020-06-16 | 赛诺菲 | Stabilized glycerol-free pharmaceutical preparations of insulin analogs and/or insulin derivatives |
| US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| WO2015104311A1 (en) * | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| US12186374B2 (en) | 2014-12-12 | 2025-01-07 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients |
| US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients |
Also Published As
| Publication number | Publication date |
|---|---|
| CY217A (en) | 1961-03-27 |
| MY6100048A (en) | 1961-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB840870A (en) | Improvements in or relating to insulin preparations | |
| GB1214733A (en) | A method for the preparation of stannous salt/palladium compositions | |
| GB1160314A (en) | Acidified Hydrogen Peroxide Solutions for Dissolving Metals | |
| JPS5642970A (en) | Redox battery | |
| GB1038678A (en) | Compounds having an adrenocorticotrophic hormone action and process for their manufacture | |
| GB907303A (en) | Improvements in or relating to the production of semi-conductor devices | |
| GB1310610A (en) | Electro-less nickel plating compositions | |
| Jaffe et al. | Studies on prolactin inhibition of thyroxine-induced metamorphosis in Rana catesbeiana tadpoles | |
| GB1395502A (en) | Herbicidal compositions | |
| GB835638A (en) | Insulin crystal suspensions having a protracted effect | |
| GB1289693A (en) | ||
| US2959520A (en) | Stabilized aqueous solution of vitamin b complex containing cyanocobalamin and thiocyanates | |
| GB748857A (en) | Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity | |
| Hellman et al. | Glucose inhibits 45Ca efflux from pancreatic β-cells also in the absence of Na+-Ca2+ countertransport | |
| GB889769A (en) | Slowly acting insulin preparation in crystalline form | |
| GB1488807A (en) | Agents for the selective combating of weeds | |
| GB929220A (en) | Gold plating | |
| GB860515A (en) | Improvements in or relating to insulin preparations | |
| ES464642A1 (en) | Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulphamyl-benzolc acid and process for their manufacture | |
| GB594355A (en) | Improvements in or relating to silver solder alloys | |
| GB709927A (en) | Improved process for producing insulin preparations with protracted effect | |
| GB1386584A (en) | Method of preparation of purine sugar derivatives | |
| GB1492106A (en) | Gelatine dessert composition | |
| GB751425A (en) | Manufacture of injectable insulin preparations with protracted effect | |
| GB812575A (en) | Improvements in or relating to sweetening compositions and method for making same |